Company intelligence · NYSE: NVO

Novo Nordisk: pipeline and clinical trials

Novo Nordisk, the maker of semaglutide, is developing CagriSema, a combination of semaglutide and the amylin analogue cagrilintide. CagriSema was submitted to the FDA in December 2025, and Novo sponsors about 146 active clinical trials.

Legal name (SEC)NOVO NORDISK A S
ListingNYSE: NVO
HeadquartersBagsværd, Denmark
SEC filingsEDGAR (CIK 353278)
Focus areasObesity, Diabetes, Cardiovascular disease, Rare blood disorders

Key points

  • Novo Nordisk sponsors 146 active trials on ClinicalTrials.gov, 50 of them in Phase 3. Obesity is the most frequently listed condition.
  • CagriSema was submitted to the FDA for weight management in December 2025. Novo anticipated a decision by late 2026 (company-reported).
  • In REDEFINE 4, CagriSema did not meet its primary endpoint of non-inferiority to Lilly's tirzepatide for weight loss (company-reported).
  • Its largest active Phase 3 trials include ARTEMIS (ziltivekimab, 10,000 participants) and AMBIENCE (zenagamtide, 8,500 participants).
  • REDEFINE 3, a 7,101-participant cardiovascular outcomes trial of CagriSema, has an estimated primary completion in September 2027.

Tracked drug profiles

Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.

Active clinical trials

ClinicalTrials.gov lists 146 active trials with Novo Nordisk as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Novo Nordisk A/S".

By phase

Phase 143
Phase 1/21
Phase 210
Phase 350
Phase 44
Not applicable38

Most common conditions

  • Obesity (67)
  • Overweight (40)
  • Diabetes Mellitus, Type 2 (18)
  • Type 2 Diabetes (10)
  • Haemophilia A (7)
  • Heart Failure (6)
  • Cardiovascular Risk (5)
  • Chronic Kidney Disease (5)

Conditions as registered by the sponsor; one trial can list several.

Largest active Phase 3 trials

TrialEnrollmentPrimary completion
ARTEMIS · NCT06118281
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
10,000Jan 29, 2027
AMBIENCE · NCT07861100
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
8,500Sep 16, 2030
REDEFINE 3 · NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
7,101Sep 1, 2027
HF-POLARIS · NCT07567001
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
5,610Jul 23, 2029
REDEFINE 1 · NCT05567796
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
3,400Oct 30, 2024
NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
2,500Feb 23, 2028
AMBITION 7 · NCT07797335
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
1,778Jul 31, 2028
FOCUS · NCT03811561
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
1,500Nov 7, 2027
REDEFINE · NCT07919405
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
1,408Jun 1, 2028
CLEOPATTRA · NCT07207811
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
1,280Jun 29, 2029

See this sponsor’s trials on ClinicalTrials.gov

Where CagriSema fits

Semaglutide, sold as Wegovy and Ozempic, built Novo Nordisk's position in obesity and diabetes. CagriSema is its attempt to go further by adding a second hormone pathway, amylin. The head-to-head REDEFINE 4 result means CagriSema enters a market where Lilly's tirzepatide has shown at least comparable weight loss.

Beyond obesity

The registry shows Novo running large cardiovascular programs with other investigational drugs, including ARTEMIS (ziltivekimab) and HF-POLARIS (NNC0487-0111) in heart failure. Spectral Genomics does not yet profile these drugs.

What to watch

  • The FDA decision on CagriSema for weight management.
  • REDEFINE 3, CagriSema's cardiovascular outcomes trial.
  • A higher-dose CagriSema trial, expected to read out in the first half of 2028 (company-reported).

Recent milestones

  1. Jun 22, 2025REDEFINE 1 and REDEFINE 2 results published in the New England Journal of Medicine. Peer-reviewed
  2. Dec 2025CagriSema submitted to the U.S. FDA for weight management. Company-reported
  3. Feb 23, 2026Novo reports REDEFINE 4 did not show non-inferiority to tirzepatide on weight loss. Company-reported
  4. Aug 4, 2026Novo reports REDEFINE 9 (lower doses) success and REIMAGINE 4 results in type 2 diabetes. Company-reported

Sources

  1. SEC EDGAR: Novo Nordisk A/S filings (CIK 353278).Regulator
  2. Novo Nordisk A/S. Form 6-K (February 23, 2026).Company-reported
  3. Novo Nordisk A/S. Form 6-K, company announcement No 48/2026 (August 4, 2026).Company-reported
  4. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025;393(7):635–647.Peer-reviewed
  5. ClinicalTrials.gov: active trials with this lead sponsorRegistry

This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.